These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. [Experience with Arvin therapy in aged patients]. Landgraf H; Stumpf J; Knecht H; Raithel D Ther Ggw; 1979 Mar; 118(3):375-86. PubMed ID: 432855 [No Abstract] [Full Text] [Related]
13. [Modified dosage scheme for the subcutaneous use of arvin in patients with chronic arterial occlusive diseases]. Ehrly AM; Köhler HJ Vasa; 1976; 5(2):155-62. PubMed ID: 973426 [No Abstract] [Full Text] [Related]
14. [Chronic arterial occlusive disease: early and late results after semi-ambulatory treatment with serpent enzyme (Arvin)]. Staiger J; Hausch W; Keil G; Konrad S Vasa; 1979; 8(4):314-9. PubMed ID: 543247 [No Abstract] [Full Text] [Related]
15. Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog. Daniel TM; Pizzo SV; Mckee PA Ann Surg; 1976 Aug; 184(2):223-8. PubMed ID: 952568 [TBL] [Abstract][Full Text] [Related]
16. [Therapeutic lowering of fibrinogen levels]. Ernst E MMW Munch Med Wochenschr; 1983 May; 125(21):83-4. PubMed ID: 6410202 [No Abstract] [Full Text] [Related]
18. [Arvin--a new therapeutic agent]. Ehrly AM Med Welt; 1978 Jul; 29(27-28):1144-5. PubMed ID: 672584 [No Abstract] [Full Text] [Related]
19. Long-term results after defibrinogenation by Arwin in chronic occlusive arterial disease. Staiger J; Konrad-Graf S; Keil G Bibl Haematol; 1981; (47):252-7. PubMed ID: 7337665 [No Abstract] [Full Text] [Related]
20. SDS polyacrylamide gel characterization of serum FDP produced in response to ancrod and streptokinase/plasminogen infusion in man. Lane DA; Robbins A; Rampling MW; Kakkar VV Br J Haematol; 1977 May; 36(1):137-48. PubMed ID: 871418 [No Abstract] [Full Text] [Related] [Next] [New Search]